Norton Waterford Ltd

General

Total Cases17

Active Cases2

Patents360

CourtsD. New Jersey D. Delaware S.D. Florida

TypeOperating Company

Elite Ratings

--

nortonhealthcare.com

norton-healthcare

norton-healthcare

Ratings

Experience

Grade

Trend

DCT

L4

E

PTAB

L4

D

CAFC

L5

E

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
02/11/25	Teva Branded Pharmaceutical Products R&D LLC v. Armstrong Pharmaceuticals Inc 1:24-CV-00869 ( D. DE )	Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # [1] Dismissal)(mdb) (Entered: 02/11/2025)
02/11/25	Teva Branded Pharmaceutical Products R&D LLC v. Armstrong Pharmaceuticals Inc 1:24-CV-00869 ( D. DE )	SO ORDERED re [25] CONSENT ORDER OF DISMISSAL ***Civil Case Terminated. Signed by Judge Maryellen Noreika on 2/11/2025. (dlw) (Entered: 02/11/2025)
02/10/25	Teva Branded Pharmaceutical Products R&D LLC v. Armstrong Pharmaceuticals Inc 1:24-CV-00869 ( D. DE )	Consent Order of Dismissal by Teva Branded Pharmaceutical Products R&D, Inc., Norton (Waterford) Ltd., Teva Pharmaceuticals USA, Inc. (Keller, Karen) Modified on 2/11/2025 (dlw). (Entered: 02/10/2025)
02/10/25	Teva Branded Pharmaceutical Products R&D LLC v. Armstrong Pharmaceuticals Inc 1:24-CV-00869 ( D. DE )	Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Norton (Waterford) Ltd., Teva Branded Pharmaceutical Products R&D, Inc., Teva Pharmaceuticals USA, Inc. filed by Teva Branded Pharmaceutical Products R&D, Inc., Norton (Waterford) Ltd., Teva Pharmaceuticals USA, Inc.. (Keller, Karen) (Entered: 02/10/2025)
02/10/25	Teva Branded Pharmaceutical Products R&D LLC v. Armstrong Pharmaceuticals Inc 1:24-CV-00869 ( D. DE )	NOTICE of Change of Name and Request to Update Party's Name on Docket by Teva Branded Pharmaceutical Products R&D, Inc., Norton (Waterford) Ltd., Teva Pharmaceuticals USA, Inc. (Keller, Karen) (Entered: 02/10/2025)
02/03/25	Teva Branded Pharmaceutical Products R&D Inc v. Cipla USA Inc 2:24-CV-09691 ( D. NJ )	TEXT ORDER: There shall be a telephone conference before the Undersigned on May 13, 2025, at 3:00 p.m. The parties shall dial 1-855-244-8681 and enter access code 2302-026-0103 to join the call. Additionally, in light of 24-9691's consolidation with 24-909, the February 13, 2025 Rule 16 Conference in 24-9691 is canceled. So Ordered by Magistrate Judge Michael A. Hammer on 2/3/25. (tad) (Entered: 02/03/2025) TEXT ORDER: There shall be a telephone conference before the Undersigned on May 13, 2025, at 3:00 p.m. The parties shall dial 1-855-244-8681 and enter access code 2302-026-0103 to join the call. Additionally, in light of 24-9691's consolidation with 24-909, the February 13, 2025 Rule 16 Conference in 24-9691 is canceled. So Ordered by Magistrate Judge Michael A. Hammer on 2/3/25. (tad) (Entered: 02/03/2025)
02/03/25	Teva Branded Pharmaceutical Products R&D Inc v. Cipla USA Inc 2:24-CV-09691 ( D. NJ )	AMENDED PRETRIAL SCHEDULING ORDER, that Civil Action No. 24-9691(SRC)(MAH) is hereby consolidated with Civil Action Nos. 24-909(SRC)(MAH)(consolidated), for all purposes, including discovery, case management, and trial. Civil Action No. 24-909(SRC)(MAH) shall be the lead case, and all filings shall be made only in Civil Action No. 24-909(SRC)(MAH). Signed by Magistrate Judge Michael A. Hammer on 2/3/2025. (wh) (Entered: 02/03/2025) AMENDED PRETRIAL SCHEDULING ORDER, that Civil Action No. 24-9691(SRC)(MAH) is hereby consolidated with Civil Action Nos. 24-909(SRC)(MAH)(consolidated), for all purposes, including discovery, case management, and trial. Civil Action No. 24-909(SRC)(MAH) shall be the lead case, and all filings shall be made only in Civil Action No. 24-909(SRC)(MAH). Signed by Magistrate Judge Michael A. Hammer on 2/3/2025. (wh) (Entered: 02/03/2025)
02/03/25	Teva Branded Pharmaceutical Products R&D Inc v. Cipla USA Inc 2:24-CV-09691 ( D. NJ )	***Civil Case Terminated pursuant to [16] AMENDED PRETRIAL SCHEDULING ORDER (consolidating cases). (wh) (Entered: 02/03/2025)
01/31/25	Teva Branded Pharmaceutical Products R&D Inc v. Cipla USA Inc 2:24-CV-09691 ( D. NJ )	Letter from Liza M. Walsh to the Honorable Michael A. Hammer, U.S.M.J. re 14 Order,,. (Attachments: # [1] Text of Proposed Order)(WALSH, LIZA) (Entered: 01/31/2025)
01/23/25	Teva Branded Pharmaceutical Products R&D Inc v. Cipla USA Inc 2:24-CV-09691 ( D. NJ )	TEXT ORDER: The Court is in receipt of the parties' stipulation and proposed order 59 . It appears the parties intended to consolidate Civil Action 24-9691 with the consolidated Civil Action 24-909. On or before January 31, 2025, the parties shall file a proposed order that makes it clear that Civil Action 24-9691 is being consolidated into Civil Action 24-909 and that Civil Action 24-909 is the lead case. This order shall also contain a fulsome, amended schedule for all tasks and deadlines in the same format as the August 13, 2024 scheduling order 38 . So Ordered by Magistrate Judge Michael A. Hammer on 1/23/25. (tad) (Entered: 01/23/2025) TEXT ORDER: The Court is in receipt of the parties' stipulation and proposed order 59 . It appears the parties intended to consolidate Civil Action 24-9691 with the consolidated Civil Action 24-909. On or before January 31, 2025, the parties shall file a proposed order that makes it clear that Civil Action 24-9691 is being consolidated into Civil Action 24-909 and that Civil Action 24-909 is the lead case. This order shall also contain a fulsome, amended schedule for all tasks and deadlines in the same format as the August 13, 2024 scheduling order 38 . So Ordered by Magistrate Judge Michael A. Hammer on 1/23/25. (tad) (Entered: 01/23/2025)